Evaluation and interference of serum and skin lesion levels of leukotrienes in patients with eczema.
To evaluate the levels of leukotrienes (LTs), interleukin-2 (IL-2), interleukin-4 (IL-4), interferon-gamma (IFN-gamma) in patients with eczema and observe the effects inversed by mizolastine. Serum LTB4, LTC4, IL-2, IL-4, IFN-gamma and urinary LTE4 levels were detected by enzyme-linked immunosorbent assay (ELISA) and LTB4, LTC4, LTE4 concentrations of cutis tissue were measured by reverse-phase high-pressure liquid chromatography (RP-HPLC) in 10 eczema patients and 10 healthy volunteers. Eczema patients received mizolastine 10 mg once a day for 5 days, respectively, for comparison between before and after treatment. The above markers were assayed again after treatment. Serum LTB4, LTC4, IL-2, IFN-gamma and urinary LTE4 and skin tissue LTB4, LTC4, LTE4 levels in patients are higher than those in healthy volunteers significantly (P < 0.05). But serum IL-4 level did not show significant difference between patients and normal controls (P > 0.05). Mizolastine significantly reduced serum LTB4 and IFN-gamma levels as well as skin lesion LTB4, LTC4, LTE4 concentrations. LTs are involved in the pathogenesis of eczema. Mizolastine clearly reduces LTs levels in skin lesion.
Hua
Zhong
Z
Department of Dermatology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
Fei
Hao
H
Mingming
Xiang
X
D000293:Adolescent; D000328:Adult; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000494:pharmacology; D016022:Case-Control Studies; D004485:Eczema / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000032:analysis; D007376:Interleukin-2 / Q000032:analysis; D015847:Interleukin-4 / Q000032:analysis; D007975:Leukotriene B4 / Q000032:analysis / Q000097:blood; D017997:Leukotriene C4 / Q000032:analysis / Q000097:blood; D017999:Leukotriene E4 / Q000032:analysis / Q000097:blood; D015289:Leukotrienes / Q000032:analysis* / Q000097:blood; D008297:Male; D008875:Middle Aged; D012867:Skin / Q000737:chemistry* / Q000473:pathology; D016896:Treatment Outcome
D001562:Benzimidazoles; D007376:Interleukin-2; D015289:Leukotrienes; D007975:Leukotriene B4; D015847:Interleukin-4; C076170:mizolastine; D017997:Leukotriene C4; D017999:Leukotriene E4; D007371:Interferon-gamma